A Unique GSK-3ß inhibitor B10 Has a Direct Effect on Aß, Targets Tau and Metal Dyshomeostasis, and Promotes Neuronal Neurite Outgrowth.
Cells
; 9(3)2020 03 07.
Article
em En
| MEDLINE
| ID: mdl-32155989
ABSTRACT
Due to the complicated pathogenesis of Alzheimer's disease (AD), the development of multitargeted agents to simultaneously interfere with multiple pathological processes of AD is a potential choice. Glycogen synthase kinase-3ß (GSK-3ß) plays a vital role in the AD pathological process. In this study, we discovered a novel 1H-pyrrolo[2,3-b]pyridine derivative B10 as a GSK-3ß inhibitor that features with a quinolin-8-ol moiety to target the metal dyshomeostasis of AD. B10 potently inhibited GSK-3ß with an IC50 of 66 ± 2.5 nM. At the concentration of 20 µM, B10 increased ß-catenin abundance (ß-catenin/GAPDH 0.83 ± 0.086 vs. 0.30 ± 0.016), phosphorylated GSK-3ß at Ser9 (p-GSK-3ß/GAPDH 0.53 ± 0.045 vs. 0.35 ± 0.012), and decreased the phosphorylated tau level (p-tau/GAPDH 0.33 ± 0.065 vs. 0.83 ± 0.061) in SH-SY5Y cells. Unlike other GSK-3ß inhibitors, B10 had a direct effect on Aß by inhibiting Aß1-42 aggregation and promoting the Aß1-42 aggregate disassociation. It selectively chelated with Cu2+, Zn2+, Fe3+, and Al3+, and targeted AD metal dyshomeostasis. Moreover, B10 effectively increased the mRNA expression of the recognized neurogenesis markers, GAP43, N-myc, and MAP-2, and promoted the differentiated neuronal neurite outgrowth, possibly through the GSK-3ß and ß-catenin signal pathways. Therefore, B10 is a potent and unique GSK-3ß inhibitor that has a direct on Aß and serves as a multifunctional anti-AD agent for further investigations.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neuritos
/
Proteínas tau
/
Glicogênio Sintase Quinase 3 beta
/
Neurônios
Limite:
Humans
Idioma:
En
Revista:
Cells
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
China